Compare Symbotic Inc (SYM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Symbotic Inc vs TG Therapeutics Inc — how do they compare? Symbotic Inc trades at $42.63 (market cap $5.46B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Symbotic Inc for 23 Days and TG Therapeutics Inc for 16 Days on average.
| SYM | TGTX | |
|---|---|---|
Market Cap | $5.46B | $8.16B |
Volume | 1,965,805 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $87.30 | $59.06 |
52-Week Low | $38.22 | $26.94 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $3.72B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYM trades at $42.06, down 2.89% on the day, with technical indicators showing bearish momentum. The company reported negative net income of -$16.94M for 2025 despite $2.25B revenue, though 2026 projections show potential improvement to $8M net profit. Analyst sentiment is mixed with 61% buy ratings but a bearish technical outlook. Recent news highlights Symbotic's $22.5B backlog and AI-driven warehouse automation growth potential.
The stock faces near-term pressure from recent earnings misses and negative profitability, but long-term growth prospects remain supported by strong backlog and AI adoption trends. Key risks include customer concentration with Walmart representing 85% of revenue and execution challenges in scaling operations. The consensus price target of $60.33 suggests 43% upside potential if the company can achieve projected profitability improvements.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
